Phenomix Sciences Raises $7.8M in Funding to Accelerate Adoption of Obesity Precision Medicine

Phenomix Sciences, a precision medicine biotechnology company that brings data intelligence to the treatment of obesity, has secured $5.5 million in Series A funding from new investors, DexCom, Inc. and Labcorp, and existing investors, including Health2047. The company has also been awarded a $2.3 million Phase II Small Business Innovation Research (SBIR) Grant through the National Institutes of Health (NIH). 

“As leaders in their respective fields of lab testing and patient empowerment, we are excited to add DexCom and Labcorp as investors as we continue to scale our company. In addition, Labcorp will provide laboratory testing services,” said Mark Bagnall, CEO of Phenomix. “After more than a decade of research from our founders, we are thrilled the wider industry is also seeing the need to treat the obesity epidemic seriously with clinically focused solutions. The substantial financial backing for Phenomix’s clinically validated precision obesity programs from prominent companies in the health industry underscores the importance precision medicine is poised to have on combating obesity.”

This capital will accelerate the commercialization and adoption of the MyPhenome™ test in the obesity specialist market and the wider industry. The MyPhenome test equips physicians with essential tools to develop effective treatment plans including lifestyle and diet intervention as well as medication and/or procedure recommendations. The MyPhenome test identifies obesity phenotypes, subtypes of the disease caused by the interaction of a patient’s genes and the environment. These phenotypes include Hungry Gut, Hungry Brain and Emotional Hunger. As demonstrated by Phenomix’s co-founders and Mayo Clinic physicians, Andres Acosta, M.D. Ph.D. and Michael Camilleri, M.D. D.Sc., obesity phenotypes help explain why people exhibit varying responses to different treatments.

The funds will also enable the company to develop and launch additional phenotyping tests, continue to support clinical studies and patent novel insights, and further strategic relationships with pharmaceutical companies and health care providers. 

The SBIR grant allows the company to perform additional clinical studies demonstrating the value of obesity precision medicine. The sizable award from the NIH is a testament to the importance of this work on the future of obesity treatment as well as the esteemed reputation of Phenomix’s founders and significance of their prior studies. Specifically, the grant will fund a prospective study of the MyPhenome test and further prove its accuracy in predicting obesity treatment response.